P2RY8

Summary

P2RY8 (P2Y receptor family member 8, HGNC:15524) is a protein-coding gene on chromosome Xp22.33 and Yp11.3, encoding S-geranylgeranyl-glutathione receptor P2RY8 (Q86VZ1). G protein-coupled receptor for S-geranylgeranyl-glutathione (GGG), an endogenous metabolite present in lymphoid tissues.

The protein encoded by this gene belongs to the family of G-protein coupled receptors, that are preferentially activated by adenosine and uridine nucleotides. This gene is moderately expressed in undifferentiated HL60 cells, and is located on both chromosomes X and Y.

Source: NCBI Gene 286530 — RefSeq curated summary.

At a glance

• Gene–disease (curated): systemic lupus erythematosus (Moderate, GenCC)
• Clinical variants (ClinVar): 16 total — 1 likely-pathogenic
• Druggable target: yes
• Cancer driver (intOGen): activating (oncogene-like) across 4 cancer types
• MANE Select transcript: NM_178129

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15524
Approved symbol	P2RY8
Name	P2Y receptor family member 8
Location	Xp22.33 and Yp11.3
Locus type	gene with protein product
Status	Approved
Aliases	P2Y8
Ensembl gene	ENSG00000182162
Ensembl biotype	protein_coding
OMIM	300525
Entrez	286530

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 8 protein_coding

ENST00000381297, ENST00000460672, ENST00000882679, ENST00000882680, ENST00000882681, ENST00000882682, ENST00000960525, ENST00000960526

RefSeq mRNA: 8 — MANE Select: NM_178129 NM_001424186, NM_001424187, NM_001424188, NM_001424189, NM_001424190, NM_001424191, NM_001424192, NM_178129

CCDS: CCDS14115

Canonical transcript exons

ENST00000381297 — 2 exons

Exon	Start	End
ENSE00001337924	1536921	1537185
ENSE00001488116	1462581	1466582

Expression profiles

Bgee: expression breadth ubiquitous, 167 present calls, max score 97.35.

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	97.35	gold quality
granulocyte	CL:0000094	95.07	gold quality
blood	UBERON:0000178	91.09	gold quality
bone marrow cell	CL:0002092	90.36	gold quality
bone marrow	UBERON:0002371	89.58	gold quality
leukocyte	CL:0000738	89.53	gold quality
monocyte	CL:0000576	88.90	gold quality
lymph node	UBERON:0000029	88.66	gold quality
trabecular bone tissue	UBERON:0002483	87.49	gold quality
epithelium of nasopharynx	UBERON:0001951	87.00	gold quality
vermiform appendix	UBERON:0001154	86.28	gold quality
ileal mucosa	UBERON:0000331	85.86	gold quality
spleen	UBERON:0002106	82.63	gold quality
superficial temporal artery	UBERON:0001614	79.90	gold quality
caecum	UBERON:0001153	79.73	gold quality
thymus	UBERON:0002370	77.04	gold quality
right lobe of thyroid gland	UBERON:0001119	76.79	gold quality
left lobe of thyroid gland	UBERON:0001120	76.43	gold quality
tonsil	UBERON:0002372	76.36	gold quality
thyroid gland	UBERON:0002046	75.90	gold quality
right adrenal gland cortex	UBERON:0035827	74.40	gold quality
left adrenal gland cortex	UBERON:0035825	73.45	gold quality
right adrenal gland	UBERON:0001233	73.12	gold quality
left adrenal gland	UBERON:0001234	73.04	gold quality
adrenal cortex	UBERON:0001235	73.01	gold quality
adrenal gland	UBERON:0002369	71.83	gold quality
small intestine Peyer’s patch	UBERON:0003454	71.36	gold quality
gall bladder	UBERON:0002110	71.31	gold quality
oviduct epithelium	UBERON:0004804	70.64	gold quality
apex of heart	UBERON:0002098	70.53	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-6075	yes	166.62
E-MTAB-9067	yes	11.15
E-GEOD-106540	no	663.53
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting P2RY8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4283	100.00	66.42	2097
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-765	99.84	68.24	2442
HSA-MIR-4307	99.82	70.45	3374
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-11181-3P	99.75	66.38	2205
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-33A-3P	99.70	70.27	3362
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-3679-3P	99.64	69.88	1599
HSA-MIR-9851-3P	99.63	69.68	1110
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-4472	99.56	66.08	1478
HSA-MIR-888-3P	99.53	69.77	1057

Literature-anchored findings (GeneRIF, showing 10)

• P2RY8 is expressed in leukemic cells and has an unexpected role in the pathogenesis of acute leukemia (PMID:17487742)
• SOX5 is upregulated by promoter swapping with the P2RY8 gene in primary splenic follicular lymphoma (PMID:17554380)
• Study reports an extremely high incidence of relapse (71% +/- 19%) in non-high-risk precursor B-cell acute lymphoblastic leukemia patients with P2RY8-CRLF2 rearrangement. (PMID:20378752)
• Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. (PMID:22484421)
• P2RY8-CRLF2-positive clones do not have the necessary proliferative or selective advantage to evolve into a disease-relevant relapse clone. (PMID:23091296)
• P2RY8 promotes clustering of activated B cells within follicles in a follicular dendritic cell (FDC)-dependent manner. (PMID:26573295)
• P2RY8-CRLF2 fusion is associated with childhood B-cell acute lymphoblastic leukemia. (PMID:27637012)
• S-Geranylgeranyl-L-glutathione(GGG) is identified as an intercellular signalling molecule that is involved in organizing and controlling germinal-centre responses; as the P2RY8 locus is modified in several other types of cancer in addition to GCB-DLBCL and Burkitt lymphoma, GGG might have organizing and growth-regulatory roles in multiple human tissues (PMID:30842656)
• [Clinical Features and Prognosis of Acute Lymphoblastic Leukemia Children with P2RY8-CRLF2 Gene Rearrangement]. (PMID:33812392)
• P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance. (PMID:34889940)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
danio_rerio	p2ry8	ENSDARG00000055560

Paralogs (16): P2RY10 (ENSG00000078589), GPR18 (ENSG00000125245), F2RL3 (ENSG00000127533), GPR55 (ENSG00000135898), LPAR6 (ENSG00000139679), GPR65 (ENSG00000140030), GPR17 (ENSG00000144230), LPAR4 (ENSG00000147145), CYSLTR2 (ENSG00000152207), F2RL2 (ENSG00000164220), F2RL1 (ENSG00000164251), CYSLTR1 (ENSG00000173198), GPR4 (ENSG00000177464), GPR35 (ENSG00000178623), F2R (ENSG00000181104), GPR20 (ENSG00000204882)

Protein

Protein identifiers

S-geranylgeranyl-glutathione receptor P2RY8 — Q86VZ1 (reviewed: Q86VZ1)

Alternative names: P2Y purinoceptor 8

All UniProt accessions (2): Q86VZ1, A0A1B0GUR3

UniProt curated annotations — full annotation on UniProt →

Function. G protein-coupled receptor for S-geranylgeranyl-glutathione (GGG), an endogenous metabolite present in lymphoid tissues. Couples the binding of GGG to the activation of GNA13 and downstream repression of AKT activation in lymphocytes defining their positioning and growth within lymphoid organs. In lymphoid follicles, confines B cells and follicular helper T cells in germinal centers (GCs) in response to GGG local gradients established by GGT5 (via GGG catabolism) and ABCC1 (via extracellular transport) with lower concentrations of GGG found in the follicular dendritic cell network region around which germinal centers are formed. In the bone marrow, also in response to GGG gradients established by GGT5 and ABCC1, it restricts chemotactic transmigration of B cells, T cells and NK cells from blood vessels to the bone marrow parenchyma. Contributes to GNA13-dependent pathway that suppresses GC B cell growth.

Subcellular location. Cell membrane.

Tissue specificity. Barely detectable in normal blood leukocytes. Weaker expression was seen in heart, kidney and lung. Not detected in brain. Expressed in B cells and follicular helper T cells in germinal centers (at protein level).

Induction. Down-regulated during granulocytic differentiation.

Miscellaneous. The gene coding for this protein is located in the pseudoautosomal region 1 (PAR1) of X and Y chromosomes.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (8): NP_001411115, NP_001411116, NP_001411117, NP_001411118, NP_001411119, NP_001411120, NP_001411121, NP_835230* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR027669	P2Y8_rcpt	Family

Pfam: PF00001

UniProt features (25 total): topological domain 8, transmembrane region 7, mutagenesis site 6, glycosylation site 2, chain 1, region of interest 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9ECJ	ELECTRON MICROSCOPY	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q86VZ1-F1	84.42	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 5, 11

Mutagenesis-validated functional residues (6):

Position	Phenotype
30	loss of protein expression at the cell surface.
163	loss of protein expression at the cell surface.
164	loss of protein expression at the cell surface.
205	loss of protein expression at the cell surface.
206	loss of protein expression at the cell surface.
290	no effect on protein expression at the cell surface.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 49 (showing top): GOBP_G_PROTEIN_COUPLED_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY, KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION, GOBP_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, KRIGE_RESPONSE_TO_TOSEDOSTAT_6HR_DN, MODULE_358, LEE_DIFFERENTIATING_T_LYMPHOCYTE, chrXp22, chrYp11, GOBP_G_PROTEIN_COUPLED_RECEPTOR_SIGNALING_PATHWAY, MODULE_525, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GOMF_NUCLEOTIDE_RECEPTOR_ACTIVITY, ARID5B_TARGET_GENES

GO Biological Process (5): G protein-coupled receptor signaling pathway (GO:0007186), Rho-activating G protein-coupled receptor signaling pathway (GO:0160221), signal transduction (GO:0007165), Rho protein signal transduction (GO:0007266), G protein-coupled purinergic nucleotide receptor signaling pathway (GO:0035589)

GO Molecular Function (2): G protein-coupled receptor activity (GO:0004930), G protein-coupled purinergic nucleotide receptor activity (GO:0045028)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor activity	2
G protein-coupled receptor signaling pathway	2
signal transduction	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
small GTPase-mediated signal transduction	1
purinergic nucleotide receptor signaling pathway	1
transmembrane signaling receptor activity	1
purinergic nucleotide receptor activity	1
G protein-coupled purinergic nucleotide receptor signaling pathway	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1384 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
P2RY8	CRLF2	Q9HC73	953
P2RY8	NEXMIF	Q5QGS0	853
P2RY8	JAK2	O60674	741
P2RY8	IKZF1	Q13422	730
P2RY8	PAX5	Q02548	701
P2RY8	GNA13	Q14344	688
P2RY8	EBF1	Q9UH73	670
P2RY8	ASMTL	O95671	667
P2RY8	ETV6	P41212	645
P2RY8	PHF6	Q8IWS0	642
P2RY8	EPOR	P19235	628
P2RY8	CSF2RA	P15509	627
P2RY8	IGHV4-38-2	P0DP08	622
P2RY8	TSLP	Q969D9	585
P2RY8	NUP214	P35658	570

IntAct

12 interactions, top by confidence:

A	B	Type	Score
RAMP1	P2RY8	psi-mi:“MI:0915”(physical association)	0.400
P2RY8	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
P2RY8	RAMP2	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	P2RY8	psi-mi:“MI:0915”(physical association)	0.400
RAMP2	P2RY8	psi-mi:“MI:0915”(physical association)	0.400
P2RY8		psi-mi:“MI:0914”(association)	0.350
P2RY8	GFAP	psi-mi:“MI:0914”(association)	0.350
P2RY8	BTAF1	psi-mi:“MI:0914”(association)	0.350
P2RY8	CIT	psi-mi:“MI:0914”(association)	0.350

BioGRID (218): ATP1A2 (Affinity Capture-MS), ATP1A4 (Affinity Capture-MS), GFAP (Affinity Capture-MS), ATP2B3 (Affinity Capture-MS), METTL9 (Affinity Capture-MS), FANCD2 (Affinity Capture-MS), BRAT1 (Affinity Capture-MS), DNAAF5 (Affinity Capture-MS), PLEKHG4 (Affinity Capture-MS), TUBA3C (Affinity Capture-MS), GNAZ (Affinity Capture-MS), ATM (Affinity Capture-MS), C1orf112 (Affinity Capture-MS), ND1 (Affinity Capture-MS), ERAP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A6I8PUB9, O00155, O00270, O14842, O14843, O15529, O43603, O46685, O60755, O88626, O88634, O88853, O88854, O88855, P0C5I1, P46092, P46093, P50132, Q149R9, Q15722, Q15743, Q1JQB3, Q3T181, Q3UFD7, Q3ZC80, Q4KLH9, Q6XKD3, Q76JU8, Q76JU9, Q76JV1, Q86VZ1, Q8BUD0, Q8BYC4, Q8HYC3, Q8K3T4, Q8TDS5, Q8TDU9, Q920E0, Q924U0, Q96G91

Diamond homologs: A5PLE7, B0UXR0, B5X337, D4A7K7, F1MV99, O08858, O35210, O35811, O77590, O88634, P11613, P21556, P25025, P25095, P25104, P25106, P26824, P29089, P29754, P29755, P30555, P30556, P30937, P30938, P31391, P32249, P32250, P32300, P33396, P33535, P34976, P35346, P35366, P35372, P35373, P35383, P41143, P41231, P41232, P42866

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 4 cancer types — BL, DLBCLNOS, MLYM, NHL.

Clinical variants and AI predictions

ClinVar

16 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
800347	NM_178129.5(P2RY8):c.869C>G (p.Pro290Arg)	Likely pathogenic

SpliceAI

796 predictions. Top by Δscore:

Variant	Effect	Δscore
X:1466581:CT:C	acceptor_gain	1.0000
X:1466581:CTCTG:C	acceptor_loss	1.0000
X:1466582:TC:T	acceptor_loss	1.0000
X:1466583:CT:C	acceptor_loss	1.0000
X:1536916:CTCA:C	donor_loss	1.0000
X:1536917:TCAC:T	donor_loss	1.0000
X:1536918:CAC:C	donor_loss	1.0000
X:1536920:C:A	donor_loss	1.0000
X:1466578:GGGCT:G	acceptor_gain	0.9900
X:1466579:GGCT:G	acceptor_gain	0.9900
X:1466580:GCT:G	acceptor_gain	0.9900
X:1466581:CTC:C	acceptor_gain	0.9900
X:1466582:TCT:T	acceptor_gain	0.9900
X:1466583:C:CC	acceptor_gain	0.9900
X:1466584:T:C	acceptor_loss	0.9900
X:1536915:GCTCA:G	donor_loss	0.9900
X:1536919:A:AC	donor_gain	0.9800
X:1536920:C:CC	donor_gain	0.9800
X:1466583:C:G	acceptor_gain	0.9700
X:1466586:C:CT	acceptor_gain	0.9600
X:1466587:A:T	acceptor_gain	0.9500
X:1511259:TC:T	donor_gain	0.9300
X:1511260:C:CT	donor_gain	0.9200
X:1511261:T:TT	donor_gain	0.9200
X:1467479:C:CT	donor_gain	0.9100
X:1468667:TTGT:T	acceptor_gain	0.9100
X:1483162:G:A	donor_gain	0.9100
X:1467427:A:AC	donor_gain	0.9000
X:1467428:C:CC	donor_gain	0.9000
X:1475558:G:T	acceptor_gain	0.9000

AlphaMissense

4634 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
Y:1466031:G:C	F176L	0.998
Y:1466031:G:T	F176L	0.998
Y:1466033:A:G	F176L	0.998
Y:1466205:G:C	S118R	0.998
Y:1466205:G:T	S118R	0.998
Y:1466207:T:G	S118R	0.998
Y:1466292:C:A	W89C	0.998
Y:1466292:C:G	W89C	0.998
Y:1465713:G:C	S282R	0.997
Y:1465713:G:T	S282R	0.997
Y:1465715:T:G	S282R	0.997
Y:1465809:G:C	F250L	0.997
Y:1465809:G:T	F250L	0.997
Y:1465811:A:G	F250L	0.997
Y:1465953:G:C	F202L	0.997
Y:1465953:G:T	F202L	0.997
Y:1465955:A:G	F202L	0.997
Y:1465690:G:T	P290Q	0.996
Y:1465821:A:C	F246L	0.996
Y:1465821:A:T	F246L	0.996
Y:1465823:A:G	F246L	0.996
Y:1466029:T:A	D177V	0.996
Y:1466034:G:C	C175W	0.996
Y:1466035:C:T	C175Y	0.996
Y:1466272:C:G	C96S	0.996
Y:1466272:C:T	C96Y	0.996
Y:1466273:A:T	C96S	0.996
Y:1466361:G:C	S66R	0.996
Y:1466361:G:T	S66R	0.996
Y:1466363:T:G	S66R	0.996

dbSNP variants (sampled 300 via entrez): RS10552339 (X:1480393 GTTTT>G,GT,GTT,GTTT,GTTTTT,GTTTTTT,GTTTTTTT), RS10563406 (X:1535726 CAG>C), RS10657765 (X:1504315 CAA>C,CA,CAAA,CAAAA,CAAAAA), RS10700341 (X:1497639 C>CAA), RS10715183 (X:1480296 CTTT>C,CT,CTT,CTTTT,CTTTTT), RS10715184 (X:1480516 TA>T), RS111065312 (X:1462110 C>T), RS111065313 (X:1472858 A>C,G), RS111065314 (X:1530414 C>A,T), RS111066038 (X:1473389 A>C,G,T), RS111161756 (X:1473080 G>A,C,T), RS111161757 (X:1473111 G>C), RS111161759 (X:1473177 A>C,G), RS111161760 (X:1473181 G>A,C), RS111161761 (X:1473591 A>G,T)

Disease associations

OMIM: gene MIM:300525 | disease phenotypes: MIM:254500

GenCC curated gene-disease

Disease	Classification	Inheritance
systemic lupus erythematosus	Moderate	Autosomal dominant

Mondo (2): plasma cell myeloma (MONDO:0009693), systemic lupus erythematosus (MONDO:0007915)

Orphanet (2): Multiple myeloma (Orphanet:29073), AL amyloidosis (Orphanet:85443)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008180	Lupus Erythematosus, Systemic	C17.300.480; C20.111.590
D009101	Multiple Myeloma	C04.557.595.500; C14.907.454.460; C15.378.147.780.650; C15.378.463.515.460; C20.683.515.845; C20.683.780.650

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4523886 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Class A Orphans with emerging pharmacology

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
Leflunomide	increases expression	1
Benzene	increases expression	1
Benzo(a)pyrene	decreases expression	1
Caffeine	increases phosphorylation	1
Cisplatin	decreases expression	1
Methyl Methanesulfonate	decreases expression	1
Nickel	increases expression	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	decreases expression	1
Antirheumatic Agents	decreases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4883573	Binding	PRESTO-Tango GPCRome screening (P2RY8)	Data for DCP probe UCSF924

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A085	YCUB-5	Cancer cell line	Male
CVCL_KY78	PathHunter CHO-K1 P2RY8 beta-arrestin	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

600 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00120887	PHASE4	COMPLETED	Lupus Atherosclerosis Prevention Study
NCT00125307	PHASE4	COMPLETED	Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis
NCT00188188	PHASE4	UNKNOWN	Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease
NCT00371501	PHASE4	COMPLETED	Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus
NCT00392093	PHASE4	COMPLETED	Effect of Hormone Replacement Therapy on Lupus Activity
NCT00413361	PHASE4	COMPLETED	The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS
NCT00508898	PHASE4	WITHDRAWN	The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria
NCT00668330	PHASE4	COMPLETED	Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus
NCT00739050	PHASE4	TERMINATED	Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)
NCT00815282	PHASE4	COMPLETED	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
NCT00828178	PHASE4	COMPLETED	Efficacy of Fish Oil in Lupus Patients
NCT00866229	PHASE4	UNKNOWN	Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level
NCT00911521	PHASE4	COMPLETED	Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study
NCT01101802	PHASE4	COMPLETED	Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)
NCT01112215	PHASE4	COMPLETED	Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations
NCT01151644	PHASE4	UNKNOWN	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
NCT01276782	PHASE4	WITHDRAWN	Levothyroxine in Pregnant SLE Patients
NCT01322308	PHASE4	COMPLETED	Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus
NCT01359826	PHASE4	WITHDRAWN	The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients
NCT01597492	PHASE4	COMPLETED	A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
NCT01632241	PHASE4	COMPLETED	Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
NCT01705977	PHASE4	COMPLETED	Belimumab Assessment of Safety in SLE
NCT01753401	PHASE4	COMPLETED	Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
NCT02270970	PHASE4	UNKNOWN	Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
NCT02477150	PHASE4	COMPLETED	Safety and Immunogenicity of a Zoster Vaccine in SLE
NCT02741960	PHASE4	COMPLETED	The Effect of Metformin on Reducing Lupus Flares
NCT02779153	PHASE4	WITHDRAWN	Acthar SLE (Systemic Lupus Erythematosus)
NCT02953821	PHASE4	COMPLETED	Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
NCT03042260	PHASE4	UNKNOWN	Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous
NCT03098823	PHASE4	COMPLETED	A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE
NCT03122431	PHASE4	COMPLETED	Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
NCT03543839	PHASE4	RECRUITING	Trial of Belimumab in Early Lupus
NCT04447053	PHASE4	UNKNOWN	Sequential Belimumab and T-cell Based Therapy in SLE
NCT04515719	PHASE4	COMPLETED	Efficacy and Safety of Belimumab in SLE Patients
NCT04893161	PHASE4	UNKNOWN	A Model About the Response of Belimumab in SLE
NCT04908865	PHASE4	COMPLETED	Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04956484	PHASE4	COMPLETED	Belimumab In Early Systemic Lupus Erythematosus
NCT05559671	PHASE4	RECRUITING	Safety of the Herpes Zoster Subunit Vaccine in Lupus
NCT05666336	PHASE4	UNKNOWN	Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients
NCT05748925	PHASE4	COMPLETED	Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients